USPTO 2015–2025 USPTO PatentsView US Corporation

Haemonetics Corporation

USPTO PatentsView assignee record - 61 granted patents across 22 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor).

RSS updates for this company

The verdict

According to USPTO PatentsView, Haemonetics ranks #5,592 of 49,997 tracked US assignees by granted-patent volume, with 61 patents across 22 technology areas.

#5,592
of 49,997 US assignees by volume
Top 11%
by Innovation Score (52.1/100)
23.8
avg claims per patent
+59%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R5592 · US Corporation #5,592 · 61 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-SMALL 61 grants
  • UPPER-Q #5,592/49,997
  • PHOTO-FINISH Gen Digital
  • CPC-FOCUS A61M · 22 areas
  • INNOV-PAR 52.1/100
  • CLAIMS-DENSE 23.8 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-SURGE +59% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Gen Digital Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Haemonetics

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Haemonetics's Innovation Score is 52.1/100 (top 11% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Haemonetics's grants concentrate

Haemonetics Corporation is a focused PatentsView assignee: 22 CPC subclasses with 60.7% of grants classified under A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor). Peak complete grant year is 2023 (11 grants) versus a trough of 2 in 2018. By volume, Haemonetics sits between Groz-beckert KG and Inpria Corporation.

Haemonetics's three-year grant acceleration

Haemonetics Corporation shows 20 grants in 2022–2024 against only 19 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Haemonetics's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Haemonetics holds 61 patents at rank #5,593, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Haemonetics

By rank, the assignees closest to #5,593 in granted patent volume.

Leaders in A61M (Devices FOR Introducing Media Into)

Other assignees with the most granted patents in Haemonetics's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Haemonetics, neither rank-band nor same-CPC leaders (those blocks stay above).

Haemonetics's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

52 Top 11% higher than 89% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

024681012 20152016201720182019202020212022202320242025 4
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Haemonetics Corporation patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 3 4.9%
2016 8 13.1%
2017 5 8.2%
2018 2 3.3%
2019 4 6.6%
2020 7 11.5%
2021 8 13.1%
2022 2 3.3%
2023 11 18.0%
2024 7 11.5%
2025partial year 4 6.6%

Which technologies does Haemonetics Corporation patent most?

Top 15 of 22 technology areas

Where it ranks

Overall rank by patents

#5,592

of 49,997 tracked assignees

Innovation Score

52.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Haemonetics Corporation's patent record in context - here's where to go next.

  • Haemonetics Corporation's lead technology class is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor), 60.7% of its portfolio - see every assignee active in that class. Explore A61M
  • Ranked #5,592 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Haemonetics Corporation against Groz-beckert KG, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 52.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.